Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

  • End date
    Mar 1, 2024
  • participants needed
  • sponsor
    Massachusetts General Hospital
Updated on 22 August 2021
gilbert's syndrome
neutrophil count


This research study is studying a combination of drugs as a possible treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The names of the study drugs involved in this study are:

  • obinutuzumab
  • venetoclax
  • acalabrutinib


This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of investigational drugs to learn whether the drugs work in treating a specific disease. "Investigational" means that the drugs are being studied.

The U.S. Food and Drug Administration (FDA) has approved [1] venetoclax- obinutuzumab and [2] acalabrutinib individually as treatment options for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). However, the combination of all 3 drugs has not yet been approved by the FDA.

  • Venetoclax is a targeted therapy drug that works by blocking a protein called Bcl-2 in cancer cells. Bcl-2 helps cancer cells survive and resist the effects of cancer treatments. By blocking Bcl-2, venetoclax may kill cancer cells and/or make them more open to the effects of other cancer treatments.
  • Obinutuzumab is a drug that targets a protein called CD20, which is found on the surface of B cells, the white blood cells that are affected by CLL. When obinutuzumab attaches to CD20, it directly both destroys the B cells and makes them more "visible" to the immune system. The immune system then attacks and destroys the cancerous B cells.
  • Acalabrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). BTK is a protein inside of the cell that may be over-expressed in malignant B cells. It is involved in the signaling pathway from the B-cell receptor. BTK inhibition caused by taking acalabrutinib results in decreased malignant B-cell growth and survival.

On this study, participants will receive obinutuzumab and venetoclax. We will monitor for minimal residual disease (MRD) using a test called "Adaptive ClonoSEQ" after treatment with obinutuzumab and venetoclax. MRD is a molecular test, which can detect whether there is any evidence of CLL/SLL in the blood or bone marrow. For participants with detectable MRD despite treatment with obinutuzumab and venetoclax, acalabrutinib will be added with the goal of achieving undetectable MRD. Additionally, for participants who have progressive CLL/SLL despite venetoclax and obinutuzumab, acalabrutinib will be added.

The research study procedures include screening for eligibility, study treatment, end of treatment visit, follow-up visits and an off-study visit.

  • Participants will receive study treatment for 2 or 3 years.
  • Participants will be followed for 2 years after completion of the study.
  • It is expected that 40 people will take part in this research study
  • Genentech is supporting this research study by providing venetoclax and obinutuzumab.

Condition small lymphocytic lymphoma, chronic lymphocytic leukemia (cll), Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, leukemia chronic lymphocytic, b-cell small lymphocytic lymphoma
Treatment Obinutuzumab, venetoclax, acalabrutinib
Clinical Study IdentifierNCT04560322
SponsorMassachusetts General Hospital
Last Modified on22 August 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of CLL or SLL according to WHO criteria
Participants must require therapy according to iwCLL 2018 guidelines
Participants must have 2 points (high or intermediate risk disease) according to the CLL
BALL Risk Model
Beta-2 microglobulin If 5 mg/L, assign 1 point
Lactate dehydrogenase If >institutional upper limit of normal, assign 1 point
Hemoglobin If <11 g/dL (female) or <12 g/dL (male), assign 1 point
Time from start of last therapy If <24 months, assign 1 point, If 4 points, patient is high risk, If 2-3 points, patient is intermediate risk, If 0-1 points, patient is low risk
Participants must have received prior systemic therapy for CLL
Age over 18 years
ECOG performance status 2 (Karnofsky 60%, see Appendix A)
Participants must have adequate organ function as defined below
total bilirubin 2 institutional upper limit of normal unless considered secondary to Gilbert's syndrome, in which case 3 x ULN
AST(SGOT)/ALT(SGPT) 2 institutional upper limit of normal
creatinine within normal institutional limits OR
creatinine clearance 30 mL/min according to the Cockcroft-Gault Equation for participants with creatinine levels above institutional normal
Participants must have adequate marrow function as defined below (unless clearly due to disease under study per investigator discretion)
absolute neutrophil count 1,000/mcL
platelets 75,000/mcL OR
> 20,000/mcL if thrombocytopenia is clearly due to disease under study (per investigator discretion)
For females of childbearing potential, a negative serum pregnancy test within 7 days of study treatment
For female patients of childbearing potential and male patients with partners of childbearing potential, agreement (by patient and/or partner) to use highly effective form(s) of contraception (i.e., one that results in a low failure rate [<1% per year] when used consistently and correctly) and to continue its use for 90 days after the last dose of acalabrutinib or venetoclax AND for 18 months after the last dose of obinutuzumab (whichever date is later)
The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception
Willingness to not donate sperm or oocytes during the entire study treatment period and after treatment discontinuation
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

Prior therapy with a BTK inhibitor (e.g. acalabrutinib) or BCL2 inhibitor (e.g. venetoclax), with the following exception
Patients with undetectable MRD by flow cytometry at 10 (peripheral blood or bone marrow) or CR from prior treatment with BCL2 inhibitor (with or without BTK inhibitor) are eligible. Note: Patients who received prior BTK inhibitor therapy alone are not eligible
Known hypersensitivity (IgE-mediated) reaction to obinutuzumab or to any of its excipients
Participants who are receiving any other investigational agents unless authorized by the overall study principal investigator
Known active histological transformation from CLL to an aggressive lymphoma (i.e., Richter's transformation)
Active malignancy or systemic therapy for another malignancy within 3 years; local/regional therapy with curative intent such as surgical resection or localized radiation within 3 years of treatment is permitted; active prostate cancer that is considered low-risk and appropriate for continued active surveillance strategy is permitted
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 2 weeks prior to Cycle 1, Day 1
Known bleeding diathesis
Pregnant women are excluded from this study because the study agents have potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with the study agents, breastfeeding should be discontinued if the mother is treated with study therapy
Prior major surgical procedure within 4 weeks of study, or anticipation of need for a major surgical procedure during the course of the study
Known CNS hemorrhage or stroke within 6 months of the study
History of progressive multifocal leukoencephalopathy (PML)
History of HIV infection or active hepatitis B (chronic or acute) or hepatitis C infection
Patients with occult or prior HBV infection (defined as positive total hepatitis B core antibody [HBcAb] and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to take appropriate anti-viral prophylaxis as indicated and undergo monthly DNA testing
Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA
Congestive heart failure, New York Heart Association classification III/IV
Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
Known condition or other clinical situation that would affect oral absorption
Psychiatric illness/social situations that would interfere with study compliance
Receipt of therapy with strong inhibitors or inducers of CYP3A, CYP2C8, CYP2C9 and CYP2C19, within 7 days prior to the first dose of study drug administration
Consumption of grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study drug administration
Requires dual antiplatelet therapy or anticoagulation with warfarin
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note